Liquidity and Management's Plans (Details) (USD $)	1 Months Ended			3 Months Ended		6 Months Ended		12 Months Ended		6 Months Ended
	May 31, 2012	Jan. 31, 2012	Mar. 31, 2011	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011	Dec. 31, 2011	Dec. 31, 2010	Jun. 30, 2012 Maximum [Member]	Jun. 30, 2012 Minimum [Member]	Feb. 28, 2012 Expired [Member]	Feb. 24, 2012 Active [Member]	Jun. 30, 2012 Contract Revenue [Member]
Liquidity and Management's Plan (Textual) [Abstract]
Securities for potential future issuance												$ 50,000,000	$ 40,000,000
Estimated cost in connection to reformulation project										800,000	600,000
Deferred contract				16,555,520		16,555,520		14,154,720						2,500,000
Liquidity and Management's Plan (Additional Textual) [Abstract]
Contract revenue from the Endo license agreement						45,000,000
Previously deferred contract revenue						100,000
Net proceeds from a private placement offering of Common Stock in March 2011			14,000,000
Net royalties under the meda agreements							34,225	1,000,000
Exercise of Common Stock warrants							1,749,259	1,700,000
Contract revenue from licensing and supply agreement								300,000
Research revenues from various contractor agreements					33,606	14,200	226,843	200,000
Exercise of Common Stock options						410,402	349,676	300,000
Expiration of potential future issuance						2015-02
Cash and cash equivalents				43,030,542	21,188,100	43,030,542	21,188,100	10,750,205	18,208,659
Cash from operations						32,952,532	(12,943,884)
Stockholders' equity				28,061,123		28,061,123		4,120,393
Upfront non-refundable milestone payment from Endo	15,000,000	30,000,000
Aggregate Anticipated cash For Clinical research				$ 45,000,000		$ 45,000,000